Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
The purpose of this clinical research study is to find out if the drugs dabrafenib and trametinib are safe and beneficial in people with BRAF mutation positive LGG or relapsed or refractory BRAF mutation positive HGG.
Participants will not be paid for their participation.
- IRB Number: 1803872717 (PHO-FERG-NOVARTIS-36G2201)
- Research Study Identifier: TX8998
- Principal Investigator: Michael Ferguson, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required